HC Wainwright Issues Pessimistic Forecast for JBIO Earnings

Jade Biosciences, Inc. (NASDAQ:JBIO) – Investment analysts at HC Wainwright dropped their Q2 2026 earnings per share (EPS) estimates for shares of Jade Biosciences in a report issued on Tuesday, May 12th. HC Wainwright analyst A. He now expects that the company will post earnings of ($0.62) per share for the quarter, down from their prior forecast of ($0.50). HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for Jade Biosciences’ current full-year earnings is ($2.34) per share. HC Wainwright also issued estimates for Jade Biosciences’ Q3 2026 earnings at ($0.63) EPS, Q4 2026 earnings at ($0.63) EPS, FY2026 earnings at ($2.45) EPS, FY2027 earnings at ($2.58) EPS, FY2028 earnings at ($2.63) EPS, FY2029 earnings at ($2.66) EPS and FY2030 earnings at ($2.04) EPS.

Jade Biosciences (NASDAQ:JBIO) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.05).

JBIO has been the topic of a number of other reports. William Blair raised Jade Biosciences to a “strong-buy” rating in a research note on Monday, March 9th. BTIG Research upped their price target on Jade Biosciences from $28.00 to $39.00 and gave the stock a “buy” rating in a research note on Monday, March 16th. Lifesci Capital raised Jade Biosciences to a “strong-buy” rating in a research note on Friday, March 6th. Weiss Ratings downgraded Jade Biosciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday. Finally, Stifel Nicolaus set a $40.00 price target on Jade Biosciences in a research note on Friday, March 6th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.33.

Jade Biosciences Price Performance

Shares of NASDAQ:JBIO opened at $25.07 on Thursday. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -12.41 and a beta of 1.52. The business’s 50-day moving average is $18.49 and its 200-day moving average is $15.36. Jade Biosciences has a 1 year low of $6.57 and a 1 year high of $28.00.

Institutional Trading of Jade Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Y Intercept Hong Kong Ltd bought a new stake in Jade Biosciences during the 1st quarter worth approximately $353,000. Invesco Ltd. grew its holdings in shares of Jade Biosciences by 477.6% in the fourth quarter. Invesco Ltd. now owns 199,727 shares of the company’s stock valued at $3,082,000 after acquiring an additional 165,151 shares in the last quarter. Ikarian Capital LLC bought a new position in shares of Jade Biosciences in the fourth quarter valued at approximately $4,629,000. Virtus Investment Advisers LLC bought a new position in shares of Jade Biosciences in the fourth quarter valued at approximately $274,000. Finally, Opaleye Management Inc. bought a new position in shares of Jade Biosciences in the fourth quarter valued at approximately $6,598,000.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small?molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.